Skip to main content
. 2013 Feb;20(1):e13–e20. doi: 10.3747/co.20.1055

FIGURE 2.

FIGURE 2

Kaplan–Meier estimates of progression-free survival (pfs) at 10 years in the zoledronic acid (zol, n = 151) and control arms (n = 157). The 10-year pfs rate was significantly higher (p < 0.001) in the zol arm than in the control arm (66% vs. 52%; 95% confidence interval: 60% to 73% vs. 46% to 57%).